Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Ulrika Ericson

Ulrika Ericson

Associate professor

Ulrika Ericson

Vitamin B6 catabolism and lung cancer risk : Results from the Lung Cancer Cohort Consortium (LC3)

Author

  • H. Zuo
  • P. M. Ueland
  • Midttun
  • G. S. Tell
  • A. Fanidi
  • W. Zheng
  • X. Shu
  • Y. Xiang
  • J. Wu
  • R. Prentice
  • M. Pettinger
  • C. A. Thomson
  • G. G. Giles
  • A. Hodge
  • Q. Cai
  • W. J. Blot
  • M. Johansson
  • J. Hultdin
  • K. Grankvist
  • V. L. Stevens
  • M. L. McCullough
  • S. J. Weinstein
  • D. Albanes
  • R. G. Ziegler
  • N. D. Freedman
  • N. E. Caporaso
  • A. Langhammer
  • K. Hveem
  • M. Næss
  • J. E. Buring
  • I. Lee
  • J. M. Gaziano
  • G. Severi
  • X. Zhang
  • M. J. Stampfer
  • J. Han
  • A. Zeleniuch-Jacquotte
  • L. L. Marchand
  • J. Yuan
  • R. Wang
  • W. Koh
  • Y. Gao
  • U. Ericson
  • K. Visvanathan
  • M. R. Jones
  • C. Relton
  • P. Brennan
  • M. Johansson
  • A. Ulvik

Summary, in English

Background Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal-5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods For this study, we included 5323 incident lung cancer cases and 5323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models. Results PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95% CI: 1.36-2.10), men (OR: 1.60, 95% CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95% CI: 1.34-2.23). Conclusion Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.

Department/s

  • EpiHealth: Epidemiology for Health
  • EXODIAB: Excellence in Diabetes Research in Sweden
  • Diabetes - Cardiovascular Disease

Publishing year

2019

Language

English

Pages

478-485

Publication/Series

Annals of Oncology

Volume

30

Issue

3

Document type

Journal article

Publisher

Oxford University Press

Topic

  • Cancer and Oncology

Keywords

  • inflammation
  • lung cancer
  • Lung Cancer Cohort Consortium
  • nested case-control study
  • PAr
  • vitamin B6

Status

Published

Research group

  • Diabetes - Cardiovascular Disease

ISBN/ISSN/Other

  • ISSN: 0923-7534